Yvonne Freund-Levi

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi request reprint Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms
    Yvonne Freund-Levi
    Department of NVS, Section of Clinical Geriatrics, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Int J Geriatr Psychiatry 23:161-9. 2008
  2. doi request reprint Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial
    Yvonne Freund-Levi
    Division of Clinical Geriatrics, Department of Neurobiology, Caring Sciences and Society NVS, Karolinska Institutet, Stockholm, Sweden Department of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden Electronic address
    Am J Geriatr Psychiatry 22:341-8. 2014
  3. doi request reprint Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study
    Yvonne Freund-Levi
    Department NVS, Division of Clinical Geriatrics, Karolinska University Hospital, Stockholm, Sweden
    Dement Geriatr Cogn Disord 27:481-90. 2009
  4. doi request reprint Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study
    Gerd Faxén-Irving
    Department of NVS, Section of Clinical Nutrition, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Alzheimers Dis 36:1-6. 2013
  5. doi request reprint Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers
    Erik Hjorth
    Division of Neurodegeneration, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    J Alzheimers Dis 35:697-713. 2013
  6. pmc Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study
    Inger Vedin
    Department of Medicine, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Lipid Res 51:1179-85. 2010
  7. pmc Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study
    Inger Vedin
    Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    PLoS ONE 7:e35425. 2012
  8. doi request reprint Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study
    Gerd Faxén Irving
    Department of Neurobiology, Karolinska Institutet, Karolinska University, Hospital Huddinge, Stockholm, Sweden
    J Am Geriatr Soc 57:11-7. 2009
  9. ncbi request reprint Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial
    Yvonne Freund-Levi
    Department of Neurobiology, Caring Sciences and Society, Section of Clinical Geriatrics, Karolinska University Hospital Huddinge, Stockholm
    Arch Neurol 63:1402-8. 2006
  10. ncbi request reprint [Omega-3-fatty acids protect against dementia. Also early symptoms of mild Alzheimer disease seem to be inhibited]
    Jan Palmblad
    Hematologiskt centrum och institutionen för medicin, Karolinska institutet och Karolinska Universitetssjukhuset Huddinge
    Lakartidningen 104:3268-71. 2007

Detail Information

Publications13

  1. ncbi request reprint Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms
    Yvonne Freund-Levi
    Department of NVS, Section of Clinical Geriatrics, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Int J Geriatr Psychiatry 23:161-9. 2008
    ..An association with APOEomega4 carriers and neuropsychiatric symptoms in AD has also been suggested...
  2. doi request reprint Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial
    Yvonne Freund-Levi
    Division of Clinical Geriatrics, Department of Neurobiology, Caring Sciences and Society NVS, Karolinska Institutet, Stockholm, Sweden Department of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden Electronic address
    Am J Geriatr Psychiatry 22:341-8. 2014
    ..To examine the effects of galantamine and risperidone on neuropsychiatric symptoms in dementia (NPSD) and global function...
  3. doi request reprint Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study
    Yvonne Freund-Levi
    Department NVS, Division of Clinical Geriatrics, Karolinska University Hospital, Stockholm, Sweden
    Dement Geriatr Cogn Disord 27:481-90. 2009
    ..omega-3 fatty acids (omega-3 FAs) found in dietary fish or fish oils are anti-inflammatory agents that may influence Alzheimer's disease (AD)...
  4. doi request reprint Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study
    Gerd Faxén-Irving
    Department of NVS, Section of Clinical Nutrition, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Alzheimers Dis 36:1-6. 2013
    ..172, p = 0.028). Thus, n - 3 FA treatment appeared to increase plasma-TTR in patients with AD. Since TTR may influence Aβ deposition in the brain, the results warrant further exploration...
  5. doi request reprint Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers
    Erik Hjorth
    Division of Neurodegeneration, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    J Alzheimers Dis 35:697-713. 2013
    ..DHA and EPA can be beneficial in AD by enhancing removal of Aβ42, increasing neurotrophin production, decreasing pro-inflammatory cytokine production, and by inducing a shift in phenotype away from pro-inflammatory M1 activation...
  6. pmc Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study
    Inger Vedin
    Department of Medicine, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Lipid Res 51:1179-85. 2010
    ..The stimulus-specific PGF(2alpha) release from PBMC after 6 months of oral supplementation with the DHA-rich fish oil might be one event related to reduced inflammatory reactions associated with omega-3 fatty acid intake...
  7. pmc Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study
    Inger Vedin
    Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    PLoS ONE 7:e35425. 2012
    ..Hence, our aim was to determine the effects of 6 mo of dietary supplementation with an n-3 FA preparation rich in DHA on global gene expression in peripheral blood mononuclear cells...
  8. doi request reprint Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study
    Gerd Faxén Irving
    Department of Neurobiology, Karolinska Institutet, Karolinska University, Hospital Huddinge, Stockholm, Sweden
    J Am Geriatr Soc 57:11-7. 2009
    ..To study the effects of omega (Omega)-3 fatty acid (FA) supplements on weight and appetite in patients with mild to moderate Alzheimer's disease (AD) in relation to inflammatory biomarkers and apolipoprotein E epsilon4 (APOEepsilon4)...
  9. ncbi request reprint Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial
    Yvonne Freund-Levi
    Department of Neurobiology, Caring Sciences and Society, Section of Clinical Geriatrics, Karolinska University Hospital Huddinge, Stockholm
    Arch Neurol 63:1402-8. 2006
    ..Epidemiologic and animal studies have suggested that dietary fish or fish oil rich in omega-3 fatty acids, for example, docosahexaenoic acid and eicosapentaenoic acid, may prevent Alzheimer disease (AD)...
  10. ncbi request reprint [Omega-3-fatty acids protect against dementia. Also early symptoms of mild Alzheimer disease seem to be inhibited]
    Jan Palmblad
    Hematologiskt centrum och institutionen för medicin, Karolinska institutet och Karolinska Universitetssjukhuset Huddinge
    Lakartidningen 104:3268-71. 2007
  11. pmc Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients
    Anton Forsberg
    Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
    Eur J Nucl Med Mol Imaging 40:580-93. 2013
    ..The aim of this study was to evaluate AZD2995 side by side with AZD2184 as novel PET radioligands for imaging of amyloid-β in Alzheimer's disease (AD)...
  12. doi request reprint Immunomodulation of microglia by docosahexaenoic acid and eicosapentaenoic acid
    Erik Hjorth
    Division of Neurodegeneration, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Curr Opin Clin Nutr Metab Care 15:134-43. 2012
    ..In this review, we present and discuss findings on the modulation of microglial activities by ω-3 FAs in vivo as well as in vitro, and propose mechanisms for their effects...
  13. ncbi request reprint [Administration of symptom-relieving drugs in Alzheimer disease is beneficial]
    Agneta Nordberg
    Geriatriska kliniken, Karolinska Universitetssjukhuset, Huddinge
    Lakartidningen 103:369-71. 2006